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Abstract A cyclic AMP specific phosphodiesterase (type IV) was purified 450,000-fold from human peripheral blood mononuclear cells through 
a sequence of chromatographic steps involving anion exchange, affinity chromatography on a matrix coupled to a derivative of the type IV inhibitor 
rolipram, and gel filtration. The enzyme showed apparent molecular masses of 70 kDa on gel filtration and 35 kDa on denaturing or native PAGE, 
indicating a possible dimerization or cleavage under certain conditions. The isoelectric point was 4.6. Kinetic parameters were K, = 2.2pM, 4 = 1.2 
PM (rolipram) and v_ = 80 pmol/min per mg protein. The most probable N-terminal sequence was determined as SLTNTNIPRF, 80% identical 
to part of the deduced amino acid sequence from cDNA sequences of PDE IV, and PDE IV,. 
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1. Introduction 
Cyclic nucleotide phosphodiesterases (PDE), which catalyze 
the hydrolysis of 3’ : S-cyclic nucleotides to the corresponding 
nucleoside S-monophosphates, play an essential role in con- 
trolling intracellular levels of cyclic nucleotides and conse- 
quently, cell function. Multiple forms of cyclic nucleotides 
phosphodiesterases differing in apparent molecular mass, chro- 
matographic properties, substrate specificity, interaction with 
certain antibodies, sensitivity to inhibitors, and mode of regula- 
tion have been identified within the same tissue and in some 
cases within the same cell [1,2]. These isoenzymes are a target 
for the development of new anti-inflammatory drugs, as indi- 
cated by the fact that many pro-inflammatory mechanisms of 
the immune system can be down-regulated by inhibitors of the 
type III (cGMP-inhibited PDE) and type IV isoenzymes (rol- 
ipram-sensitive PDE, reviewed by Torphy and Undem [3]). 
Analysis of the PDE complement of relevant cells helps to 
design the most effective anti-intlammatory compound based 
on PDE inhibition. In principle, this can be achieved either by 
homology cloning or by direct biochemical characterisation. 
Homology cloning in conjunction with detection of corre- 
sponding mRNA will yield indication of the type and amount 
of a protein potentially present cells. Direct characterisation of 
the isoenzyme activity, albeit labor-intensive, is more informa- 
tive with respect o the contribution to the overall hydrolysis 
of CAMP. Additionally the latter approach allows detection of 
post-translational processing, for example proteolytic cleavage. 
Human peripheral blood mononuclear cells were chosen for the 
direct biochemical analysis. This heterogeneous fraction con- 
tains monocytes, platelets and B and T lymphocytes. These cells 
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play important roles in the inflammatory response and are 
therefore primary targets of anti-inflammatory therapy. 
Whereas monocytes contain mostly type IV PDE, lymphocytes 
appear to have both type III and IV PDE, whilst the predom- 
inant CAMP-hydrolyzing isoenzyme in platelets is PDE-III [3]. 
In this report we describe the purification and biochemical 
characterization of the rolipram-sensitive CAMP-hydrolytic ac- 
tivity from mononuclear cells. Additionally this is, to our 
knowledge, the first account of a succesful determination of the 
N-terminal amino acid sequence of a type IV PDE. 
2. Materials and methods 
2. I. Materials 
[‘I-&AMP (specific activity 28 CYmmol), [31-IjcGMP (specific activity 
5 Cilmmol), [i4C]AMP (specific activity 0.6 Wmmol) were obtained 
from E.I. du Pont de Nemours &Co., (Inc). Snake venom (5’~nucleoti- 
dase), Histopaque 1077 and Histopaque 1119 were from Sigma 
Chemical Co. Dextran T500 and EAH-Sepharose were obtained from 
Pharmacia. Rolipram (4-[3-cyclopentyloxy-4-methoxyphenyll-2-pyrro- 
lidone) and the ligand for the afbnity column (4-[3-(carboxypropyloxy)- 
4-methoxyphenyll-2-pytrolidone) w re kindly provided by Dr. J. Dem- 
nitz, Sandoz Preclinical Research Basle, RO 20-1724 (4-[(3-butyloxy-4- 
methoxyphenyl)methyl]-2-imidazolidinone) was a generous gift from 
Hoffman-La Roche. SDS-PAGE standard proteins: phosphorylase b, 
bovine serum albumin, bovine carbonic anhydrase, soybean trypsin 
inhibitor, and lysozyme were from Bio-Rad. Other reagents were ob- 
tained commercially and were of analytical grade. 
2.2. Phosphodiesterase assay 
PDE activity was assayed using a two-step method as described [4] 
involving conversion of AMP to adenosine with 5’nucleotidase and 
separation from unreacted substrate on an anion exchange resin. The 
volume of the final mixture contained 0.3 ml assay buffer (40 mM 
Tris-HCl, pH 8, 10 mM MgCl,, 3.75 mM /I-mercaptoethanol, 0.125 
mg/ml BSA, 1 PM [3H]cAMP (10,008 cpm), [14C]AMP (4,000 cpm)) and 
0.1 ml of enzyme preparation, diluted in buffer A (see section 2.4) if 
necessary. Incubations were routinely carried out for 30 min at 37°C. 
Calmodulin stimulation experiments were done using 2 mM CaCl, and 
1 PM calmodulin. 
2.3. Cell isolation and cytosol preparation 
All extraction and purification steps were performed at 4°C except 
for aftinity chromatography was performed at room temperature 
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(20-25’C) [5]. ButTy coat units prepared from human peripheral venous 
blood were obtained from the Swiss Red Cross (Beme, Switzerland). 
Mononuclear cells were prepared by sedimentation of the erythrocytes 
under unit gravity in the presence of dextran. Separation from granulo- 
cytes was achieved by density gradient centrifugation on Histopaque 
1077/l 119. The cells were then washed three times with PBS to reduce 
platelet contamination. 
Cells were resuspended in homogenization buffer (10 mM Tris, pH 
7.4, 1 mM EDTA, 1 &ml pep&tin, 1 &ml leupeptin, 35 &ml 
PMSF, 5 &ml aprotinin, 2 mM bermamid&, 0.25 M &crose, b.i M 
NaCl. 0.25 ml/ml ethvlene lvcol and 10 me/ml CHAPS and lvsed bv 
gentle shaking, until ihe su&nsion was hgmogeneous (-30 &in). In 
preliminary experiments, cells were sonicated (Branson Cell Sonifier 
Model B12, 30 s, 50 W). After centrifugation (120,000 x g, 1 h), the 
supematant was carefully removed, pooled and immediately applied to 
Q Sepharose. 
2.4. Chromatography 
2.4.1. Separation of phosphodiesterase isoenzymes on Q Sepha- 
rose. The supematant was loaded onto a Q Sepharose column (20 ml 
bed volume) equilibrated with buffer A (10 mM Tris, pH 7.4, 1 mM 
EDTA, 1 @ml pepstatin, 1 &ml leupeptin, 5 &ml aprotinin, 2 mM 
benxamidine, 0.25 ml/ml ethylene glycol and 1 mgfml CHAPS). After 
loading, the column was washed with 5 bed volumes of buffer A con- 
taining 0.1 M NaCl and PDE activity was eluted with a linear gradient 
in buffer A of NaCl (0.1 to 0.4 M, 15 bed volumes). Fractions (6 ml) 
corresponding to different PDE activities (against cGMP, CAMP and 
CAMP plus 3 PM rolipram) were pooled and stored at -20°C prior to 
further purification. 
2.4.2. Amity chromatography and removal of CAMP on Mono Q.The 
type IV isoenxyme (showing rolipram-sensitive hydrolysis of CAMP) 
was then applied to an affiity column of the rolipram analog 4-[3- 
(carboxypropyloxy)-4-methoxyphenyl]-2-pyrrolidone coupled to EAH- 
sepharose 4B [5]. After washing with 5 bed volumes of buffer B (buffer 
A + 0.5 M NaCl, without ethylene glycol), the enzyme was eluted with 
3 bed volumes of buffer B containing 1 mM CAMP. After use, the 
column was regenerated with 6 M urea and stored in 20% ethanol. To 
remove the CAMP, the eluate from aflinity chromatography was diluted 
1:4 with buffer C (25 mM Bis-Tris, pH 6.8, 1 mM EDTA, 1 @nl 
pep&tin, 1 &ml leupeptin, 5 &ml aprotinin, 2 mM benxamidine, and 
1 m&nl CHAPS) and loaded onto a 1 ml Mono Q HR5/5 column 
(Pharmacia) equilibrated with the same buffer. After washing with 10 
bed volumes of buffer C containing 0.125 M NaCl, the PDE-IV activity 
was eluted with a linear gradient of NaCl(O.12550.425 M NaCl. 15 bed 
volumes) inbuffer C, co&cting fractions (0.5 ml) into tubes co&ning 
0.1 ml ethylene glycol. Fractions were stored at -2O’C until use. 
2.4.3. Gel filtration on Superose 12. Fractions showing rolipram- 
sensitive CAMP hydrolysis were pooled, concentrated to a volume of 
0.5 ml on Centricon- membranes (Amicon) and applied to a 12 ml HR 
10/30, Superose 12 column (Pharmacia) running at a flow rate of 0.2 
ml/min with buffer A containing 0.1 M NaCl. Fractions (250 ~1) were 
collected into tubes containing 50 ,~l ethylene glycol and stored at 
-20°c. 
2.4.4. Numerical procedures. Standard enxyme kinetic models were 
fitted to experimental data using the method of non-linear least-squares 
regression analysis as supplied by the RSll software (Bolt &ranek and 
Newman Inc.). 
2.45. Other procedures. SDS-gel electrophoresis was performed on 
12.5% Phastgels (Phastsystem, Pharmacia). The separation and silver 
staining were carried out according to the manufacturer’s instructions. 
Active fractions from the gel filtration were pooled, concentrated to 
0.14 ml on Microcon- membranes (Amicon), and applied to a 2 x 8 
mm piece of Problott membrane (Applied Biosystems). After air-dry- 
ing, the membrane was directly loaded into an automatic sequencer 
model 477A (Applied Biosystems) and the N-terminal amino acid se- 
quence determined according to Edman [6,7. Protein concentration 
was determined as described by Bradford [8]. 
3. Results 
3.1. Enzyme extraction and purt@cation 
PDE activity was released from human mononuclear cells by 
detergent lysis with minimal mechanical intervention. By com- 
parison with sonication the recovery was approximately 2 times 
lower, however it appeared that purity was increased, especially 
in the later steps. More than 90% of the activity remained in 
the supernatant after centrifugation (120,000 x g, 1 h). Storage 
at -20°C in the presence of 25% (v/v) ethylene glycol prevented 
the loss of activity seen in experiments without ethylene glycol. 
The use of a buffer containing 0.1% (w/v) CHAPS [9] in all 
chromatographic steps resulted in improved yields. 
3.1.1. Separation of PDE-isoenzymes on Q Sepharose. The first 
purification step separated PDE isoenzymes from the bulk of 
the protein using anion exchange chromatography. PDE isoen- 
zymes were identified on the basis of substrate specificity and 
inhibition of CAMP hydrolysis by rolipram. The elution profile 
(Fig. 1) shows 3 peaks of PDE activity, eluting at 170 mM (peak 
1, selective hydrolysis of cGMP, PDE-V), 260 mM (peak 2, 
selective hydrolysis CAMP inhibited by rolipram, PDE-IV), and 
340 mM (peak 3), rolipram-insensitive CAMP-hydrolyzing ac- 
tivity. This peak eluted at the same position as cGMP-inhibited 
CAMP PDE from human platelets @‘DE-III, data not shown). 
Peaks 2 and 3 accounted for 67% and 28% of the total recovered 
CAMP-PDE activity, respectively. The activity present in all 
peaks was independent of calcium-calmodulin. The fractions of 
peak 2 were pooled and stored at -20°C for further purifica- 
tion. 
3.1.2. AfJinity chromatography. Irrespective of the selectivity of 
rolipram seen in enzyme assays, the rolipram-based affinity 
matrix possesses ignificant binding capacity for PDE-III at 
0.25 M NaCl. This material can be eliminated by elution with 
buffer containing 0.5 M NaCl. Selective lution of type IV PDE 
is then achieved with buffer containing 0.5 M NaCl and 1 mM 
CAMP. Excess unlabelled CAMP in the elution buffer prevents 
accurate determination of PDE activity and must be removed 
by anion exchange chromatography. In first experiments this 
step was carried out at pH 7.4, and contaminating bands with 
~12 7 were found at later steps. These could be eliminated by 
reducing the pH of the elution buffer to pH 6.8, resulting in a 
step yield of about 67% with a 11 @O-fold increase of specific 
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Fig. 1. Q Sepharose chromatography of human mononuclear leukocyte 
extract. Phosphodiesterase activity was assayed with 1 .uM cGMP (0), 
with 1 ,uM CAMP (o), and with 1 ,uM CAMP + 3 PM rolipram (m). 
NaCl-gradient (----). 
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Fig. 2. Anion exchange chromatography (Mono Q). Activity was assayed with 1 PM CAMP (0) as substrate and with 1 PM CAMP + 3 PM rolipram 
(m). Inset: SDS-PAGE analysis of the active fractions (right lane), left lane: reference proteins with molecular masses hown in kDa. 
activity. The overall recovery was 45% with a 130,000-fold 
purification. SDS-PAGE analysis (inset of Fig. 2) revealed 5 
proteins with apparent molecular masses of 35,67, 100,31 and 
18 kDa (in decreasing order of intensity). 
3.1.3. Gelfiltration on Superose 12. On a gel filtration column, 
enzyme activity migrated with an apparent molecular mass of 
about 70 kDa, approximately at the same position as BSA (Fig. 
3). With this step, a further 3-fold purification was achieved 
with a yield of 95%. The overall recovery was 43% with a 
450,000-fold purification. SDS-PAGE analysis of the active 
fractions (41-49) showed that the band at 35 kDa corresponded 
in intensity to the protein and activity peaks on gel filtration 
(Fig. 3, inset). There was no visible staining corresponding to 
a protein of 70 kDa. The active fractions were pooled and 
stored at -20°C in the presence of 20% (v/v) ethylene glycol for 
further analysis. Data from a typical preparation are summa- 
rized in Table 1. 
3.2. Biochemical properties of the purified enzyme 
PuriGed type IV PDE hydrolyzed CAMP, but not cGMP at 
concentrations up to 10 ,uM. Hydrolysis of CAMP (1 PM) was 
inhibited by rolipram and RO 20-1724 with I&, values of 1.3 
PM and 7.9 ,uM, respectively (data not shown). When assayed 
with substrate and rolipram concentrations ranging from 0.1 
to 10 PM and 0 to 3 PM, respectively, the purified enzyme 
showed behavior compatible with Michaelis-Menten kinetics. 
Fitting the simple model of competitive inhibition (interaction 
of inhibitor with the free enzyme only, parameters v_ and KJ 
yielded a llr, of 2.2 PM and a v_ of 0.37,umollminlml at 37°C. 
By using an estimated protein concentration of 5 &ml, ob- 
tained by comparison with standard proteins on SDS-PAGE, 
Table 1 
Purification summary of CAMP specific rolipram-sensitive phosphodiesterase from 2.3. IO” human mononuclear cells 
Step Total protein Total activity Specific activity Purification 
(m8) (nmol/min) (nmoVmin/mg) (-fold) 
Supematant 120,000 x g 5,300 990 0.19 1 
Q Sepharose 300 660 2.20 12 
Rolipram-Sepharose, Mono Q 0.017* 450 25,000 130,ooo 
Superose 12 0.005’ 430 86,000 450,ooo 
*Protein concentrations were estimated from SDS-PAGE. 
Yield 
(95) 
100 
67 
45 
43 
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Fig. 3. Chromatography onSuperose 12. Activity was assayed with 1 PM CAMP (0) as substrate and with 1 PM CAMP + 3 PM rolipram (H). Azso 
is shown as (--). Inset: arrows indicate the elution position of BSA (67 kDa) and ovalbumin (45 kDa), respectively. Fraction 46 was lost during the 
concentration step. 
a specific v_ of 80 pmol/min/mg protein was calculated. The 
inhibitory constant for the competitive model was estimated as 
1.2 PM (Table 2). Alternative models of inhibition were also 
evaluated: The model assuming interaction of the inhibitor with 
the enzyme-substrate complex only (‘un-competitive’, parame- 
ters v,, and 4) fitted the data less closely, as evidenced by a 
considerably larger sum of squared residuals, and by visual 
examination of the fit (not shown). On the other hand, the 
model assuming interactions of the inhibitor with both free 
enzyme and enzyme-substrate complex (‘non-competitive’, 
parameters v_, 4 and 4) showed a slightly smaller sum of 
squared residuals than the competitive model. Within experi- 
mental error, the K,,,, $ and v,,,, were similar for the competi- 
tive and non-competitive models. For the noncompetitive 
model, the additional parameter Kj was estimated at 17 PM 
with a large standard error of 10yM. These results indicate that 
interaction of rolipram with the enzyme-substrate complex, if 
present, has little effect on the hydrolysis of CAMP by PDE-IV 
This is also supported by the essentially straight lines of the 
Lineweaver-Burk plot shown in Fig. 4 and the Dixon replot 
(inset of Fig. 4). Parameters estimated from these plots were 
similar to those obtained by nonlinear fitting (v,,,, = 0.4 
pm01 .min-’ * ml-‘, x, = 2.5 ,uM, Ki = 1.9 PM) 
3.3. N-terminal sequence 
Determination of the N-terminal amino acid sequence of the 
purified PDE-IV has been difficult to date due to the low 
abundance of this isoenzyme in most tissues and to its sensitiv- 
ity to proteolysis. Another reason for this difficulty may be that 
many cell types contain several isoenzymes of the type IV fam- 
ily [lO-121, in theory requiring selection of a tissue or cell 
containing predominantly one isoenzyme in order to obtain a 
homogeneous preparation of PDE-IV using standard purifica- 
tion methods. 
Table 2 
Model parameters for inhibition of CAMP hydrolysis by rolipram 
V 
@Zol. min-’ . ml-‘) 
&I 
WW 
Competitive 0.37 (0.01) 2.2 (0.2) 
Un-competitive 0.46 (0.03) 4.4 (0.5) 
Non-competitive 0.39 (0.01) 2.5 (0.2) 
Standard errors are in parentheses. 
fG 
WW 
1.2 (0.1) 
1.6 (0.3) 
fG 
W) 
3.0 (0.4) 
16.9 (10.1) 
C (residuals)2 
(x lo-)) 
5.4 
12 
5.1 
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Fig. 4. Lineweaver-Burk analysis of CAMP hydrolysis by pooled active 
fractions from Mono Q chromatography. Rolipram concentrations 
were 0 (o), 0.5 (0), 1 (A), 1.5 (v), and 3 ,uM (0). In the inset, slopes of 
the lines from the Lineweaver-Burk plot are plotted against inhibitor 
concentration (Dixon replot). 
Comparison of the N-terminal sequence of mononuclear cell 
PDE-IV with sequences deduced from human recombinant 
cDNA of isoenzymes IV, to IV, shows identical amino acids 
at 6 to 8 out of 10 corresponding positions (Fig. 5). As PDE-IVc 
is least similar to the N-terminal peptide found, this form is 
probably not present in mononuclear CAMP PDE. This conclu- 
sion is supported by the absence of PDE-IV, mRNA in human 
white blood cells as analyzed by reverse-transcriptase poly- 
merase chain reaction [ 131. 
It is theoretically possible that the N-terminal peptide se- 
quence is derived from a mixture of PDE-IV,, IV, and IV,. 
This however is not consistent with the data presented. Thus, 
based on the presence of Thr at position 3 of PDE-IV,, this 
isoenzyme should contribute more to the peptide sequence than 
the other forms. Similar reasoning can be applied to positions 
5 (PDE-IV,) and 6 (PDE-IV& 
4. Discussion 
By combining anion exchange chromatography and gel fil- 
tration with affinity chromatography on rolipram-Sepharose, 
the low K,,, CAMP specific, rolipram-sensitive PDE (PDE-IV, 
competitive 4 for rolipram 1.2pM) was purified _ 450,000-fold 
from human blood cells in 43% overall yield. The molecular 
mass of mononuclear cell CAMP specific PDE, as determined 
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by gel filtration, was about 70 kDa, while SDS-PAGE analysis 
showed a molecular mass of about 35 kDa, similar to non- 
denaturing PAGE analysis (data not shown). This may indicate 
that two molecules of 35 kDa either dimerize under certain 
conditions, or are cleaved while retaining enzymatic activity. 
Similarly, Thompson et al. [14] have observed a decrease of 
apparent molecular mass after storage (24 h at 4°C) or freezing 
and thawing. 
Hydrolysis of CAMP and its inhibition by rolipram obey the 
simple Michaelis-Menten model. The X, value for CAMP hy- 
drolysis estimated from our data (2.2 PM) is close to published 
values for the high-affinity component of lymphocyte CAMP 
hydrolysis [ 15,161. For PDE-IV expressed from cDNA clones, 
the values are also similar [17,18] or slightly higher, in the range 
of 7 to 10 PM [l 11. Maximum specific activity values (specific 
v,,) cited in the literature are in the range of 0.5 nmol/min/mg 
protein for lymphocyte PDE [15] and in the 50 to 300 mnol/mi& 
mg range for cloned PDE-IV expressed in yeast [ 1 l] and COS- 
cells [17], respectively. Thus, even allowing for the uncertainty 
associated with estimation of such low quantities of protein, 
our value of 80 pmol/min/mg is considerably higher than the 
reference values. This large specific activity may reflect a com- 
bination of the high purification factor and low activity loss 
obtained with the present purification procedure (Table 1). 
Sequence comparison between the mononuclear CAMP spe- 
cific PDE and the four human recombinant CAMP specific 
phosphodiesterases (IV, [11,17], IVr, [11,19,20], IVc [13] and 
IV, [ 11,121) shows at least two amino acids changes (PDE, and 
PDE,, Fig. 5). The possibility that alternative splicing might 
lead to such differences in sequence seems unlikely, as the exon 
boundaries are identical for rat PDE IVB and IV,, [21], and 
none of these exon boundaries is found within the correspond- 
ing N-terminal decapeptide of mononuclear PDE IV Although 
polymorphism may account for some inter-individual variation 
in cDNA sequences, our N-terminal sequence is representative 
of a large population of donors. It is unlikely that the N- 
terminal sequence shown in Fig. 5 is simply derived from a 
(nearly equimolar) mixture of several peptides, since the data 
presented are not consistent with such an assumption. Based 
on our data, we cannot exclude that the final preparation con- 
tains small amounts of other PDE-IV isoenzymes. However, it 
appears that we have obtained the N-terminal sequence of a 
form of PDE-IV which, on average, is the most abundant spe- 
cies in mixed mononuclear leukocytes from large numbers of 
individuals. The relative contributions of the different cell types 
(mainly B and T lymphocytes and monocytes) to the amounts 
of PDE-IV isoenzymes remains the subject of further investiga- 
tions, as does the extent of polymorphism found in the popula- 
tion. 
5 10 
MNL PDE-IV Ser-Leu-Thr-Asn-Thr-Asn-Ile-Pro-Arg-Phe- 
PDE-IVA (human) [17] . - . -Asn- . -Ser- . - . - _ - . - . - 
PDE-IV, (human) [19,201 . - . -Asn- . - . -Ser- . -Ser- . - . - 
PDE-IV, (human) [13] . - . -Pro-Thr-Ala-Ala- _ - . - . - . - 
PDE-IV, (human) [12] . - . - . - . -Ser-Ser- . - . - . - . - 
Fig. 5. Homology of the N-terminal amino acid sequence of human mononuclear PDE-IV with partial deduced amino acid sequences of the four 
groups of human cDNA clones. 
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In summary, the data presented in this paper suggest that 
human mononuclear cells contain a rolipram-sensitive (type 
IV) PDE similar but not identical to PDE-IV*, PDE-IV, or 
PDE-IVa. 
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